Research page
Tesamorelin

Specification
| Name | Tesamorelin |
|---|---|
| Catalog sizes | 10 mg |
| Adopted bacteriostatic water | 10 mg + 2.0 mL = 5 mg/mL |
Overview
Tesamorelin is an analog of growth hormone–releasing hormone (GHRH). It stimulates growth-hormone release from the pituitary; it is not growth hormone. A branded medicine that contains it is FDA-approved for a specific use in HIV-associated lipodystrophy. The TRACE vial is not that medicine.
Mechanism under study
It binds GHRH receptors in the pituitary and supports pulses of growth hormone. That signal has in turn been studied alongside insulin-like growth factor 1 (IGF-1). Clinical work has focused on visceral fat in adults with HIV-associated lipodystrophy, not on a general use.
What published research has reported
A randomized trial published in The New England Journal of Medicine in 2007 studied a growth hormone–releasing factor in adults with HIV and described changes in visceral fat compared with placebo. TRACE does not copy that trial’s regimen.
Composition and mass
The catalog offers a 10 mg vial. The adopted sheet uses 2 mL of bacteriostatic water, which leaves 5 mg/mL. That is a reconstitution figure, not an amount for use.
Reconstitution
| mg | mL | mg/mL | |
|---|---|---|---|
| 10 | 2.0 | 5 | In the catalog |
Storage and handling
Lyophilized: cool, dry, and away from light. Once dissolved: refrigerate at 2–8 °C, do not freeze, and treat the vial as material to use within 28 days.
Regulatory status
Tesamorelin is FDA-approved only as a branded medicine to reduce excess abdominal fat in HIV-associated lipodystrophy. This research vial is not that product, does not include its official diluent, and is not intended to diagnose, treat, cure, or prevent any disease.